首页 > 最新文献

Europace最新文献

英文 中文
Components of the Atrial fibrillation Better Care pathway for holistic care of patients with atrial fibrillation: a win ratio analysis from the COOL-AF registry. 为心房颤动患者提供整体护理的心房颤动更好护理(ABC)路径的组成部分:来自 COOL-AF 登记处的赢率分析。
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-30 DOI: 10.1093/europace/euae237
Rungroj Krittayaphong, Sukrit Treewaree, Gregory Y H Lip

Aims: Compliance with integrated care based on the Atrial fibrillation Better Care (ABC) pathway has been associated with improved clinical outcomes. The primary objective of this study was to compare clinical outcomes of AF patients according to the compliant status of each component of the ABC pathway in a hierarchical win ratio approach.

Methods and results: We studied AF patients in the COOL-AF registry. Each patient was followed every 6 months until 3 years. A win ratio analysis was performed, as not all clinical outcomes are equivalent. The hierarchical outcomes were (1) all-cause death, (2) intracranial haemorrhage (ICH), (3) ischaemic stroke/systemic embolism, (4) non-ICH major bleedings, and (5) acute myocardial infarction or heart failure. We also assessed win ratio and win proportion variance over the follow-up time, and the variations over time. A total of 3405 patients (mean age 67.8 ± 11.3; 41.8% female) were studied. Win ratio of ABC-compliant (all three components) vs. ABC-not-compliant was 1.57 (1.35-1.83), P < 0.001. When adding time in therapeutic range (TTR) data for compliant criteria for those who were on warfarin, the win ratio increased to 2.28 (1.89-2.75), P < 0.001. The A-compliant group (plus TTR data), B-compliant, and C-compliant had the win ratio of 1.81 (1.51-2.12), 1.82 (1.53-2.16), and 1.39 (1.18-1.62), all P < 0.001, compared to not compliant group.

Conclusion: Management of AF patients according to each component of the ABC pathway is associated with better clinical outcomes compared to those non-compliant to ABC pathway. This finding underscores the importance of a holistic management approach strategy for AF patients.

目的:遵守基于心房颤动更好护理(ABC)路径的综合护理与改善临床预后有关。本研究的主要目的是采用分层胜率法,根据心房颤动更好护理路径各组成部分的达标情况,比较心房颤动患者的临床预后:我们对 COOL-AF 登记处的房颤患者进行了研究。每名患者每 6 个月接受一次随访,直至 3 年。由于并非所有临床结果都是等效的,因此我们进行了赢率分析。分级结果为:1)全因死亡;2)颅内出血;3)缺血性中风/系统性栓塞(SSE);4)非ICH大出血;5)急性心肌梗死或心力衰竭。我们还评估了随访期间的Win比率和Win比例差异,以及随时间推移的变化。共研究了 3405 名患者(平均年龄为 67.8±11.3;41.8% 为女性)。符合 ABC 标准(所有 3 项内容)与不符合 ABC 标准的获胜比例为 1.57(1.35-1.83),P 结论:与不符合 ABC 路径的患者相比,按照 ABC 路径的每个组成部分对房颤患者进行管理可获得更好的临床疗效。这一发现强调了心房颤动患者整体管理策略的重要性。
{"title":"Components of the Atrial fibrillation Better Care pathway for holistic care of patients with atrial fibrillation: a win ratio analysis from the COOL-AF registry.","authors":"Rungroj Krittayaphong, Sukrit Treewaree, Gregory Y H Lip","doi":"10.1093/europace/euae237","DOIUrl":"10.1093/europace/euae237","url":null,"abstract":"<p><strong>Aims: </strong>Compliance with integrated care based on the Atrial fibrillation Better Care (ABC) pathway has been associated with improved clinical outcomes. The primary objective of this study was to compare clinical outcomes of AF patients according to the compliant status of each component of the ABC pathway in a hierarchical win ratio approach.</p><p><strong>Methods and results: </strong>We studied AF patients in the COOL-AF registry. Each patient was followed every 6 months until 3 years. A win ratio analysis was performed, as not all clinical outcomes are equivalent. The hierarchical outcomes were (1) all-cause death, (2) intracranial haemorrhage (ICH), (3) ischaemic stroke/systemic embolism, (4) non-ICH major bleedings, and (5) acute myocardial infarction or heart failure. We also assessed win ratio and win proportion variance over the follow-up time, and the variations over time. A total of 3405 patients (mean age 67.8 ± 11.3; 41.8% female) were studied. Win ratio of ABC-compliant (all three components) vs. ABC-not-compliant was 1.57 (1.35-1.83), P < 0.001. When adding time in therapeutic range (TTR) data for compliant criteria for those who were on warfarin, the win ratio increased to 2.28 (1.89-2.75), P < 0.001. The A-compliant group (plus TTR data), B-compliant, and C-compliant had the win ratio of 1.81 (1.51-2.12), 1.82 (1.53-2.16), and 1.39 (1.18-1.62), all P < 0.001, compared to not compliant group.</p><p><strong>Conclusion: </strong>Management of AF patients according to each component of the ABC pathway is associated with better clinical outcomes compared to those non-compliant to ABC pathway. This finding underscores the importance of a holistic management approach strategy for AF patients.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autonomic modulation impacts conduction velocity dynamics and wavefront propagation in the left atrium. 自主神经调节影响左心房的传导速度动态和波前传播。
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-30 DOI: 10.1093/europace/euae219
Shohreh Honarbakhsh, Caroline Roney, Caterina Vidal Horrach, Pier D Lambiase, Ross J Hunter

Aims: Atrial fibrosis and autonomic remodelling are proposed pathophysiological mechanisms in atrial fibrillation (AF). Their impact on conduction velocity (CV) dynamics and wavefront propagation was evaluated.

Methods and results: Local activation times (LATs), voltage, and geometry data were obtained from patients undergoing ablation for persistent AF. LATs were obtained at three pacing intervals (PIs) in sinus rhythm (SR). LATs were used to determine CV dynamics and their relationship to local voltage amplitude. The impact of autonomic modulation- pharmacologically and with ganglionated plexi (GP) stimulation, on CV dynamics, wavefront propagation, and pivot points (change in wavefront propagation of ≥90°) was determined in SR. Fifty-four patients were included. Voltage impacted CV dynamics whereby at non-low voltage zones (LVZs) (≥0.5 mV) the CV restitution curves are steeper [0.03 ± 0.03 m/s ΔCV PI 600-400 ms (PI1), 0.54 ± 0.09 m/s ΔCV PI 400-250 ms (PI2)], broader at LVZ (0.2-0.49 mV) (0.17 ± 0.09 m/s ΔCV PI1, 0.25 ± 0.11 m/s ΔCV PI2), and flat at very LVZ (<0.2 mV) (0.03 ± 0.01 m/s ΔCV PI1, 0.04 ± 0.02 m/s ΔCV PI2). Atropine did not change CV dynamics, while isoprenaline and GP stimulation resulted in greater CV slowing with rate. Isoprenaline (2.7 ± 1.1 increase/patient) and GP stimulation (2.8 ± 1.3 increase/patient) promoted CV heterogeneity, i.e. rate-dependent CV (RDCV) slowing sites. Most pivot points co-located to RDCV slowing sites (80.2%). Isoprenaline (1.3 ± 1.1 pivot increase/patient) and GP stimulation (1.5 ± 1.1 increase/patient) also enhanced the number of pivot points identified.

Conclusion: Atrial CV dynamics is affected by fibrosis burden and influenced by autonomic modulation which enhances CV heterogeneity and distribution of pivot points. This study provides further insight into the impact of autonomic remodelling in AF.

目的:心房纤维化和自主神经重塑是心房颤动(房颤)的病理生理机制。我们评估了它们对传导速度(CV)动态和波前传播的影响:从接受持续性房颤消融术的患者身上获取了局部激活时间(LATs)、电压和几何数据。局部激活时间是在窦性心律(SR)的三个起搏间隔(PIs)获得的。LAT 用于确定 CV 动态及其与局部电压振幅的关系。在窦性心律(SR)时,确定自律神经调节(药物和神经节丛(GP)刺激)对 CV 动态、波前传播和支点(波前传播变化≥90°)的影响。研究共纳入了 54 名患者。电压影响 CV 动态,在非低电压区(LVZ)(≥0.5 mV),CV 恢复曲线更陡峭[0.03 ± 0.03 m/s ΔCV PI 600-400 ms (PI1), 0.54 ± 0.09 m/s ΔCV PI 400-250 ms (PI2)],在 LVZ(0.2-0.49 mV)处更宽(0.17 ± 0.09 m/s ΔCV PI1,0.25 ± 0.11 m/s ΔCV PI2),在极 LVZ 处平坦(结论:心房 CV 动态受纤维组织的影响:心房 CV 动态受纤维化负荷的影响,并受自律神经调节的影响,自律神经调节增强了 CV 的异质性和支点的分布。本研究进一步揭示了自律神经重塑对房颤的影响。
{"title":"Autonomic modulation impacts conduction velocity dynamics and wavefront propagation in the left atrium.","authors":"Shohreh Honarbakhsh, Caroline Roney, Caterina Vidal Horrach, Pier D Lambiase, Ross J Hunter","doi":"10.1093/europace/euae219","DOIUrl":"10.1093/europace/euae219","url":null,"abstract":"<p><strong>Aims: </strong>Atrial fibrosis and autonomic remodelling are proposed pathophysiological mechanisms in atrial fibrillation (AF). Their impact on conduction velocity (CV) dynamics and wavefront propagation was evaluated.</p><p><strong>Methods and results: </strong>Local activation times (LATs), voltage, and geometry data were obtained from patients undergoing ablation for persistent AF. LATs were obtained at three pacing intervals (PIs) in sinus rhythm (SR). LATs were used to determine CV dynamics and their relationship to local voltage amplitude. The impact of autonomic modulation- pharmacologically and with ganglionated plexi (GP) stimulation, on CV dynamics, wavefront propagation, and pivot points (change in wavefront propagation of ≥90°) was determined in SR. Fifty-four patients were included. Voltage impacted CV dynamics whereby at non-low voltage zones (LVZs) (≥0.5 mV) the CV restitution curves are steeper [0.03 ± 0.03 m/s ΔCV PI 600-400 ms (PI1), 0.54 ± 0.09 m/s ΔCV PI 400-250 ms (PI2)], broader at LVZ (0.2-0.49 mV) (0.17 ± 0.09 m/s ΔCV PI1, 0.25 ± 0.11 m/s ΔCV PI2), and flat at very LVZ (<0.2 mV) (0.03 ± 0.01 m/s ΔCV PI1, 0.04 ± 0.02 m/s ΔCV PI2). Atropine did not change CV dynamics, while isoprenaline and GP stimulation resulted in greater CV slowing with rate. Isoprenaline (2.7 ± 1.1 increase/patient) and GP stimulation (2.8 ± 1.3 increase/patient) promoted CV heterogeneity, i.e. rate-dependent CV (RDCV) slowing sites. Most pivot points co-located to RDCV slowing sites (80.2%). Isoprenaline (1.3 ± 1.1 pivot increase/patient) and GP stimulation (1.5 ± 1.1 increase/patient) also enhanced the number of pivot points identified.</p><p><strong>Conclusion: </strong>Atrial CV dynamics is affected by fibrosis burden and influenced by autonomic modulation which enhances CV heterogeneity and distribution of pivot points. This study provides further insight into the impact of autonomic remodelling in AF.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":"26 9","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implantable cardioverter defibrillator therapy in paediatric patients for primary vs. secondary prevention. 儿科植入式心脏除颤器治疗的一级预防与二级预防。
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-30 DOI: 10.1093/europace/euae245
Jani Thuraiaiyah, Berit Thornvig Philbert, Annette Schophuus Jensen, Lucas Yixi Xing, Troels Hoejsgaard Joergensen, Chee Woon Lim, Frederikke Noerregaard Jakobsen, Pernille Steen Bække, Michael Rahbek Schmidt, Lars Idorn, Morten Holdgaard Smerup, Jens Brock Johansen, Sam Riahi, Jens Cosedis Nielsen, Ole De Backer, Lars Sondergaard, Christian Jons

Aims: The decisions about placing an ICD in a child are more difficult than in an adult due to longer expected lifespan and the complication risk. Young patients gain the most years from ICDs, despite higher risk of device-related complications. The secondary prevention ICD indication is clear, and device is implanted regardless of potential complications. For primary prevention, risk of sudden cardiac death and complications need to be evaluated. We aimed to compare outcomes for primary and secondary prevention ICDs.

Methods and results: Retrospective nationwide cohort study including paediatric patients identified from the Danish ICD registry with ICD implanted at an age ≤ 15 from 1982-21. Demographics, complications (composite of device-related infections or lead-failure requiring re-operation, mortality because of arrhythmia, or unknown cause), and mortality were retrieved from medical charts. Endpoint was appropriate therapy (shock or anti-tachycardia pacing for ventricular tachycardia or fibrillation). Of 72 receiving an ICD, the majority had channelopathies (n = 34) or structural heart diseases (n = 28). ICDs were implanted in 23 patients for primary prevention and 49 for secondary prevention, at median ages of 13.8 and 11.6 years (P-value 0.01), respectively. Median follow-up was 9.0 (interquartile ranges: 4.7-13.5) years. The 10-year cumulative incidence of first appropriate therapy was 70%, with complication and inappropriate therapy rates at 41% and 15%, respectively. No difference was observed between prevention groups for all outcomes. Six patients died during follow-up.

Conclusion: In children, two-thirds are secondary prevention ICDs. Children have higher appropriate therapy and complication rates than adults, while the inappropriate therapy rate was low.

目的: 由于预期寿命较长以及并发症风险较高,为儿童植入 ICD 的决定比成人更为困难。尽管 ICD 相关并发症的风险较高,但年轻患者从 ICD 中获益最多。二级预防 ICD 的适应症很明确,无论是否存在潜在并发症,都应植入设备。对于一级预防,需要评估心脏性猝死和并发症的风险。我们旨在比较一级预防和二级预防 ICD 的疗效:回顾性全国队列研究,包括从丹麦 ICD 登记处确认的在 1982-21 年间植入 ICD 年龄小于 15 岁的儿童患者。研究人员从病历中检索了患者的人口统计学特征、并发症(与设备相关的感染或需要再次手术的导联故障、心律失常导致的死亡或原因不明)和死亡率。终点是适当的治疗(针对室速或室颤的电击或抗心动过速起搏)。在 72 例接受 ICD 治疗的患者中,大多数患有通道病(34 例)或结构性心脏病(28 例)。23 名患者植入 ICD 用于一级预防,49 名患者植入 ICD 用于二级预防,中位年龄分别为 13.8 岁和 11.6 岁(P 值为 0.01)。中位随访时间为 9.0 年(四分位间范围:4.7-13.5 年)。首次适当治疗的 10 年累积发生率为 70%,并发症和不适当治疗的发生率分别为 41% 和 15%。预防组之间在所有结果上均无差别。六名患者在随访期间死亡:结论:在儿童中,三分之二是二级预防 ICD。儿童的适当治疗率和并发症发生率高于成人,而不适当治疗率较低。
{"title":"Implantable cardioverter defibrillator therapy in paediatric patients for primary vs. secondary prevention.","authors":"Jani Thuraiaiyah, Berit Thornvig Philbert, Annette Schophuus Jensen, Lucas Yixi Xing, Troels Hoejsgaard Joergensen, Chee Woon Lim, Frederikke Noerregaard Jakobsen, Pernille Steen Bække, Michael Rahbek Schmidt, Lars Idorn, Morten Holdgaard Smerup, Jens Brock Johansen, Sam Riahi, Jens Cosedis Nielsen, Ole De Backer, Lars Sondergaard, Christian Jons","doi":"10.1093/europace/euae245","DOIUrl":"10.1093/europace/euae245","url":null,"abstract":"<p><strong>Aims: </strong>The decisions about placing an ICD in a child are more difficult than in an adult due to longer expected lifespan and the complication risk. Young patients gain the most years from ICDs, despite higher risk of device-related complications. The secondary prevention ICD indication is clear, and device is implanted regardless of potential complications. For primary prevention, risk of sudden cardiac death and complications need to be evaluated. We aimed to compare outcomes for primary and secondary prevention ICDs.</p><p><strong>Methods and results: </strong>Retrospective nationwide cohort study including paediatric patients identified from the Danish ICD registry with ICD implanted at an age ≤ 15 from 1982-21. Demographics, complications (composite of device-related infections or lead-failure requiring re-operation, mortality because of arrhythmia, or unknown cause), and mortality were retrieved from medical charts. Endpoint was appropriate therapy (shock or anti-tachycardia pacing for ventricular tachycardia or fibrillation). Of 72 receiving an ICD, the majority had channelopathies (n = 34) or structural heart diseases (n = 28). ICDs were implanted in 23 patients for primary prevention and 49 for secondary prevention, at median ages of 13.8 and 11.6 years (P-value 0.01), respectively. Median follow-up was 9.0 (interquartile ranges: 4.7-13.5) years. The 10-year cumulative incidence of first appropriate therapy was 70%, with complication and inappropriate therapy rates at 41% and 15%, respectively. No difference was observed between prevention groups for all outcomes. Six patients died during follow-up.</p><p><strong>Conclusion: </strong>In children, two-thirds are secondary prevention ICDs. Children have higher appropriate therapy and complication rates than adults, while the inappropriate therapy rate was low.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":"26 9","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenging the status quo: a scoping review of value-based care models in cardiology and electrophysiology. 挑战现状:心脏病学和电生理学领域以价值为基础的护理模式范围综述。
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-30 DOI: 10.1093/europace/euae210
Lucia Osoro, Maura M Zylla, Frieder Braunschweig, Francisco Leyva, Josep Figueras, Helmut Pürerfellner, Josè Luis Merino, Ruben Casado-Arroyo, Giuseppe Boriani

Aims: The accomplishment of value-based healthcare (VBHC) models could save up to $1 trillion per year for healthcare systems worldwide while improving patients' wellbeing and experience. Nevertheless, its adoption and development are challenging. This review aims to provide an overview of current literature pertaining to the implementation of VBHC models used in cardiology, with a focus on cardiac electrophysiology.

Methods and results: This scoping review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis for Scoping Reviews. The records included in this publication were relevant documents published in PubMed, Mendeley, and ScienceDirect. The search criteria were publications about VBHC in the field of cardiology and electrophysiology published between 2006 and 2023. The implementation of VBHC models in cardiology and electrophysiology is still in its infant stages. There is a clear need to modify the current organizational structure in order to establish cross-functional teams with the patient at the centre of care. The adoption of new reimbursement schemes is crucial to moving this process forward. The implementation of technologies for data analysis and patient management, among others, poses challenges to the change process.

Conclusion: New VBHC models have the potential to improve the care process and patient experience while optimizing the costs. The implementation of this model has been insufficient mainly because it requires substantial changes in the existing infrastructures and local organization, the need to track adherence to guidelines, and the evaluation of the quality of life improvement and patient satisfaction, among others.

背景和目标:实现基于价值的医疗保健(VBHC)模式每年可为全球医疗保健系统节省高达 1 万亿美元,同时改善患者的福祉和体验。然而,其采用和发展却充满挑战。本综述旨在概述当前有关在心脏病学中实施基于价值的医疗保健模式的文献,重点关注心脏电生理学:本范围界定综述是根据《范围界定综述的系统综述和元分析首选报告项目》(Preferred Reporting Items for Systematic Reviews and Meta-analysis for Scoping Reviews)进行的。本出版物所收录的记录是发表在 PubMed、Mendeley 和 ScienceDirect 上的相关文献。检索标准为 2006 年至 2023 年间发表的心脏病学和电生理学领域有关 VBHC 的出版物:结果:VBHC 模型在心脏病学和电生理学领域的应用仍处于起步阶段。显然有必要改变当前的组织结构,以建立以患者为中心的跨职能团队。采用新的报销方案对于推进这一进程至关重要。数据分析和患者管理等技术的实施对变革进程提出了挑战:新的 VBHC 模式有可能在优化成本的同时改善护理流程和患者体验。这种模式的实施还不够充分,主要是因为它需要对现有的基础设施和地方组织进行重大变革,需要跟踪指导方针的遵守情况,以及对生活质量的改善和患者满意度等进行评估。
{"title":"Challenging the status quo: a scoping review of value-based care models in cardiology and electrophysiology.","authors":"Lucia Osoro, Maura M Zylla, Frieder Braunschweig, Francisco Leyva, Josep Figueras, Helmut Pürerfellner, Josè Luis Merino, Ruben Casado-Arroyo, Giuseppe Boriani","doi":"10.1093/europace/euae210","DOIUrl":"10.1093/europace/euae210","url":null,"abstract":"<p><strong>Aims: </strong>The accomplishment of value-based healthcare (VBHC) models could save up to $1 trillion per year for healthcare systems worldwide while improving patients' wellbeing and experience. Nevertheless, its adoption and development are challenging. This review aims to provide an overview of current literature pertaining to the implementation of VBHC models used in cardiology, with a focus on cardiac electrophysiology.</p><p><strong>Methods and results: </strong>This scoping review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis for Scoping Reviews. The records included in this publication were relevant documents published in PubMed, Mendeley, and ScienceDirect. The search criteria were publications about VBHC in the field of cardiology and electrophysiology published between 2006 and 2023. The implementation of VBHC models in cardiology and electrophysiology is still in its infant stages. There is a clear need to modify the current organizational structure in order to establish cross-functional teams with the patient at the centre of care. The adoption of new reimbursement schemes is crucial to moving this process forward. The implementation of technologies for data analysis and patient management, among others, poses challenges to the change process.</p><p><strong>Conclusion: </strong>New VBHC models have the potential to improve the care process and patient experience while optimizing the costs. The implementation of this model has been insufficient mainly because it requires substantial changes in the existing infrastructures and local organization, the need to track adherence to guidelines, and the evaluation of the quality of life improvement and patient satisfaction, among others.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11393573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shortened radiofrequency delivery time to optimize efficiency and safety of pulmonary vein isolation with the radiofrequency balloon: insights from the COLLABORATE registry. 缩短射频传输时间,优化射频球囊肺静脉隔离的效率和安全性:COLLABORATE 登记的启示。
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-30 DOI: 10.1093/europace/euae227
Alexandre Almorad, Domenico Giovanni Della Rocca, Alvise Del Monte, Johan Vijgen, Pieter Koopman, René Worck, Arne Johannessen, Caroline Lepièce, Antoine de Meester de Ravenstein, Teresa Strisciuglio, Sara Poggi, Giuseppe Stabile, Carmelo La Greca, Joseph Antoine Kheir, Laurence Jesel-Morel, Milad El Haddad, Amin Hossein, Charles Audiat, Roberto Scacciavillani, Luigi Pannone, Carlo de Asmundis, Gian-Battista Chierchia

Aims: Previous clinical studies on pulmonary vein isolation (PVI) with a radiofrequency balloon (RFB) reported safe and effective procedures using conventional ablation settings with 20/60 s RF delivery via posterior/anterior (PST/ANT) electrodes. The latest evidence suggests that reducing the application time to 15 s (s) on the posterior wall when facing the oesophageal region is as effective as applying 20 s. To prospectively assess whether reducing RF time on PST/ANT segments to 15/45 s can ensure sufficient quality of lesion metrics and compare the new shortened ablation settings with the conventional one in terms of safety, and effectiveness at 1-year.

Methods and results: A total of 641 patients from seven European centres were enrolled in a collaborative registry, with 374 in the conventional RF delivery group and 267 in the shortened RF delivery group. Procedural outcomes, lesion metrics, and safety profiles were assessed and compared between the groups. Freedom of any atrial tachycarrythmias at one year was 85.4% and 88.2% in the SHRT and CONV groups, respectively. The shortened RF delivery strategy was associated with significantly shorter procedure times (median 63.5 vs. 96.5 min, P < 0.001) and shortened fluoroscopy exposure (median 10.0 vs. 14.0 min, P < 0.001) compared to conventional delivery. Efficacy metrics, including first-pass isolation rates and time to isolation, were comparable between groups. Shortened RF delivery was associated with a lower incidence of procedural complications (1.4% vs. 5.3%, P = 0.04) and optimized thermal characteristics.

Conclusion: Analyses from the COLLABORATE registry demonstrate that shortening RF energy delivery times to 15/45 s (PST/ANT) during PVI with the RFB resulted in comparable freedom from recurrent atrial tachyarrhythmia compared to conventional delivery times with comparable efficiency and safety.

背景:之前关于使用射频球囊(RFB)进行肺静脉隔离(PVI)的临床研究报告称,使用常规消融设置,通过后/前(PST/ANT)电极进行 20/60 秒射频传输,手术安全有效。最新证据表明,在面对食管区域时,将后壁的射频应用时间缩短至 15 秒与 20 秒同样有效:前瞻性评估将 PST/ANT 区段的射频时间缩短至 15/45 秒是否能确保足够的病变指标质量,并比较新的缩短消融设置与传统消融设置的安全性和 1 年后的有效性:来自欧洲 7 个中心的 641 名患者参加了合作登记,其中 374 人属于传统射频消融组,267 人属于缩短射频消融组。对两组患者的手术结果、病变指标和安全性进行了评估和比较:结果:SHRT 组和 CONV 组一年后无任何房性快速性心律失常的比例分别为 85.4% 和 88.2%。与传统手术相比,缩短射频置管策略显著缩短了手术时间(中位数为 63.5 分钟对 96.5 分钟,P < 0.001),并缩短了透视暴露时间(中位数为 10.0 分钟对 14.0 分钟,P < 0.001)。两组的疗效指标(包括首次分离率和分离时间)相当。缩短射频给药时间与较低的手术并发症发生率(1.4% 对 5.3%,P = 0.04)和优化的热特性有关:COLLABORATE注册中心的分析表明,在使用RFB进行PVI时,将射频能量传输时间缩短至15/45秒(PST/ANT),与传统传输时间相比,可避免复发性房性快速性心律失常,且效率和安全性相当。
{"title":"Shortened radiofrequency delivery time to optimize efficiency and safety of pulmonary vein isolation with the radiofrequency balloon: insights from the COLLABORATE registry.","authors":"Alexandre Almorad, Domenico Giovanni Della Rocca, Alvise Del Monte, Johan Vijgen, Pieter Koopman, René Worck, Arne Johannessen, Caroline Lepièce, Antoine de Meester de Ravenstein, Teresa Strisciuglio, Sara Poggi, Giuseppe Stabile, Carmelo La Greca, Joseph Antoine Kheir, Laurence Jesel-Morel, Milad El Haddad, Amin Hossein, Charles Audiat, Roberto Scacciavillani, Luigi Pannone, Carlo de Asmundis, Gian-Battista Chierchia","doi":"10.1093/europace/euae227","DOIUrl":"10.1093/europace/euae227","url":null,"abstract":"<p><strong>Aims: </strong>Previous clinical studies on pulmonary vein isolation (PVI) with a radiofrequency balloon (RFB) reported safe and effective procedures using conventional ablation settings with 20/60 s RF delivery via posterior/anterior (PST/ANT) electrodes. The latest evidence suggests that reducing the application time to 15 s (s) on the posterior wall when facing the oesophageal region is as effective as applying 20 s. To prospectively assess whether reducing RF time on PST/ANT segments to 15/45 s can ensure sufficient quality of lesion metrics and compare the new shortened ablation settings with the conventional one in terms of safety, and effectiveness at 1-year.</p><p><strong>Methods and results: </strong>A total of 641 patients from seven European centres were enrolled in a collaborative registry, with 374 in the conventional RF delivery group and 267 in the shortened RF delivery group. Procedural outcomes, lesion metrics, and safety profiles were assessed and compared between the groups. Freedom of any atrial tachycarrythmias at one year was 85.4% and 88.2% in the SHRT and CONV groups, respectively. The shortened RF delivery strategy was associated with significantly shorter procedure times (median 63.5 vs. 96.5 min, P < 0.001) and shortened fluoroscopy exposure (median 10.0 vs. 14.0 min, P < 0.001) compared to conventional delivery. Efficacy metrics, including first-pass isolation rates and time to isolation, were comparable between groups. Shortened RF delivery was associated with a lower incidence of procedural complications (1.4% vs. 5.3%, P = 0.04) and optimized thermal characteristics.</p><p><strong>Conclusion: </strong>Analyses from the COLLABORATE registry demonstrate that shortening RF energy delivery times to 15/45 s (PST/ANT) during PVI with the RFB resulted in comparable freedom from recurrent atrial tachyarrhythmia compared to conventional delivery times with comparable efficiency and safety.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The triggers of situational syncope do not influence the head-up tilt test response and prognosis. 情境性晕厥的诱发因素不会影响抬头仰卧试验的反应和预后。
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-30 DOI: 10.1093/europace/euae208
Vincenzo Russo, Erika Parente, Angelo Comune, Anna Rago, Gerardo Nigro, Michele Brignole

Aims: The study evaluated the positivity rate, haemodynamic responses, and prognosis in terms of syncopal recurrence among patients with situational syncope (SS) stratified according to the underlying situational triggers.

Methods and results: We retrospectively evaluated all consecutive patients with SS who underwent nitroglycerine (NTG)-potentiated head-up tilt test (HUTT) at Syncope Unit of the University of Campania 'Luigi Vanvitelli'-Monaldi Hospital from 1 March 2017 to 1 May 2023. All patients were followed for at least one year. The study population was divided according to the underlying triggers (micturition, swallow, defaecation, cough/sneeze, post-exercise). Two hundred thirty-six SS patients (mean age 50 ± 19.3 years; male 63.1%) were enrolled; among them, the situational trigger was micturition in 109 patients (46.2%); swallow in 32 (13.6%) patients; defaecation in 35 (14.8%) patients; post-exercise in 41 (17.4%) patients; and cough/sneeze in 17 (7.2%) patients. There were no significant differences in baseline clinical characteristics and HUTT responses between different situational triggers. The Kaplan-Meier analysis did not show a statistically different rate of syncope recurrence across patients stratified by baseline situational triggers (log-rank P = 0.21).

Conclusion: Situational syncope appears to be a homogenous syndrome, and different triggers do not impact the HUTT response or syncope recurrence at 1 year.

研究目的该研究评估了根据潜在情景诱因分层的情景性晕厥(SS)患者的阳性率、血液动力学反应和晕厥复发的预后:我们对2017年3月1日至2023年5月1日期间在坎帕尼亚大学 "Luigi Vanvitelli"- Monaldi医院晕厥科接受硝酸甘油(NTG)强化HUTT的所有连续SS患者进行了回顾性评估。所有患者均接受了至少一年的随访。研究人群根据基本诱因(排尿、吞咽、排便、咳嗽/喷嚏、运动后)进行划分。结果:236 名 SS 患者(平均年龄为 50±19.3 岁;男性占 63.结果:236 名 SS 患者(平均年龄(50± 19.3)岁;男性 63.1%)入组;其中,109 名患者(46.2%)的情境诱因是排尿;32 名患者(13.6%)的情境诱因是吞咽;35 名患者(14.8%)的情境诱因是排便;41 名患者(17.4%)的情境诱因是运动后;17 名患者(7.2%)的情境诱因是咳嗽/喷嚏。不同情境诱因的基线临床特征和 HUTT 反应无明显差异。Kaplan-Meier分析显示,按基线情景触发因素分层的患者晕厥复发率没有统计学差异(log-rank p=0.21):SS似乎是一种同质综合征,不同的触发因素不会影响HUTT反应或1年后的晕厥复发率。
{"title":"The triggers of situational syncope do not influence the head-up tilt test response and prognosis.","authors":"Vincenzo Russo, Erika Parente, Angelo Comune, Anna Rago, Gerardo Nigro, Michele Brignole","doi":"10.1093/europace/euae208","DOIUrl":"10.1093/europace/euae208","url":null,"abstract":"<p><strong>Aims: </strong>The study evaluated the positivity rate, haemodynamic responses, and prognosis in terms of syncopal recurrence among patients with situational syncope (SS) stratified according to the underlying situational triggers.</p><p><strong>Methods and results: </strong>We retrospectively evaluated all consecutive patients with SS who underwent nitroglycerine (NTG)-potentiated head-up tilt test (HUTT) at Syncope Unit of the University of Campania 'Luigi Vanvitelli'-Monaldi Hospital from 1 March 2017 to 1 May 2023. All patients were followed for at least one year. The study population was divided according to the underlying triggers (micturition, swallow, defaecation, cough/sneeze, post-exercise). Two hundred thirty-six SS patients (mean age 50 ± 19.3 years; male 63.1%) were enrolled; among them, the situational trigger was micturition in 109 patients (46.2%); swallow in 32 (13.6%) patients; defaecation in 35 (14.8%) patients; post-exercise in 41 (17.4%) patients; and cough/sneeze in 17 (7.2%) patients. There were no significant differences in baseline clinical characteristics and HUTT responses between different situational triggers. The Kaplan-Meier analysis did not show a statistically different rate of syncope recurrence across patients stratified by baseline situational triggers (log-rank P = 0.21).</p><p><strong>Conclusion: </strong>Situational syncope appears to be a homogenous syndrome, and different triggers do not impact the HUTT response or syncope recurrence at 1 year.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11363866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulsed-field- vs. cryoballoon-based pulmonary vein isolation: lessons from repeat procedures. 脉冲场与冷冻球囊肺静脉隔离术:从重复手术中汲取的教训。
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-30 DOI: 10.1093/europace/euae221
Marc D Lemoine, Julius Obergassel, Sandro Jaeckle, Moritz Nies, Sophia Taraba, Celine Mencke, Jan Rieß, Ilaria My, Laura Rottner, Fabian Moser, Djemail Ismaili, Bruno Reißmann, Feifan Ouyang, Paulus Kirchhof, Andreas Rillig, Andreas Metzner

Aims: Pulsed-field ablation (PFA) is an emerging technology to perform pulmonary vein isolation (PVI). Initial data demonstrated high safety and efficacy. Data on long-term PVI durability and reconduction patterns in comparison to established energy sources for PVI are scarce. We compare findings in repeat ablation procedures after a first PFA to findings in repeat ablation procedures after a first cryoballoon ablation (CBA) based PVI.

Methods and result: A total of 550 consecutively enrolled patients underwent PFA or CBA index PVI. Repeat ablations in patients with symptomatic atrial arrhythmia recurrences were analysed. A total of 22/191 (12%) patients after index PFA-PVI and 44/359 (12%) after CBA-PVI underwent repeat ablation. Reconduction of any pulmonary vein (PV) was detected by multipolar spiral mapping catheter at each PV with careful evaluation of PV potentials and by 3D-mapping in 16/22 patients (73%) after PFA-PVI and in 33/44 (75%) after CBA-PVI (P = 1.000). Of 82 initially isolated PVs after PFA-PVI, 31 (38%) were reconducting; of 169 isolated PVs after CBA-PVI, 63 (37%) were reconducting (P = 0.936). Clinical atrial tachycardia occurred similarly in patients after PFA (5/22; 23%) and CBA (7/44; 16%; P = 0.515). Roof lines were set more often after PFA- (8/22; 36%) compared with CBA-PVI (5/44; 11%; P = 0.023). Repeat procedure duration [PFA: 87 (76, 123) min; CBA: 93 (75, 128) min; P = 0.446] was similar and fluoroscopy time [PFA: 11 (9, 14) min; CBA: 11 (8, 14) min; P = 0.739] equal between groups at repeat ablation.

Conclusion: During repeat ablation after previous PFA- or CBA-based PVI, electrical PV-reconduction rates and patterns were similar.

背景和目的:脉冲场消融(PFA)是一种新兴的肺静脉隔离(PVI)技术。初步数据显示其安全性和有效性都很高。与已有的肺静脉隔离能量来源相比,有关肺静脉隔离的长期耐久性和再传导模式的数据很少。我们比较了首次脉冲场消融(PFA)后重复消融手术的结果和首次基于低温球囊消融(CBA)的 PVI 后重复消融手术的结果。分析了有症状房性心律失常复发患者的重复消融情况:结果:共有 22/191 例(12%)PFA-PVI 指数患者和 44/359 例(12%)CBA-PVI 患者接受了重复消融术。在 PFA-PVI 后的 16/22 例患者(73%)和 CBA-PVI 后的 33/44 例患者(75%)中,通过多极螺旋测绘导管在每个肺静脉仔细评估肺静脉电位,并通过三维测绘检测到任何肺静脉(PV)的重建(P=1.000)。在 PFA-PVI 后的 82 个最初孤立的 PV 中,31 个(38%)重新传导;在 CBA-PVI 后的 169 个孤立的 PV 中,63 个(37%)重新传导(p=0.936)。临床房性心动过速在 PFA(5/22;23%)和 CBA(7/44;16%;P=0.515)术后患者中的发生率相似。与CBA-PVI(5/44;11%;P=0.023)相比,PFA-(8/22;36%)术后更常出现屋顶线。重复消融时,各组的重复手术时间(PFA:87 [76,123] 分钟;CBA:93 [75,128] 分钟;P=0.446)相似,透视时间(PFA:11 [9,14] 分钟;CBA:11 [8,14] 分钟;P=0.739)相同:结论:在进行过基于 PFA 或 CBA 的 PVI 后再次消融时,PV 电再导率和模式相似。
{"title":"Pulsed-field- vs. cryoballoon-based pulmonary vein isolation: lessons from repeat procedures.","authors":"Marc D Lemoine, Julius Obergassel, Sandro Jaeckle, Moritz Nies, Sophia Taraba, Celine Mencke, Jan Rieß, Ilaria My, Laura Rottner, Fabian Moser, Djemail Ismaili, Bruno Reißmann, Feifan Ouyang, Paulus Kirchhof, Andreas Rillig, Andreas Metzner","doi":"10.1093/europace/euae221","DOIUrl":"10.1093/europace/euae221","url":null,"abstract":"<p><strong>Aims: </strong>Pulsed-field ablation (PFA) is an emerging technology to perform pulmonary vein isolation (PVI). Initial data demonstrated high safety and efficacy. Data on long-term PVI durability and reconduction patterns in comparison to established energy sources for PVI are scarce. We compare findings in repeat ablation procedures after a first PFA to findings in repeat ablation procedures after a first cryoballoon ablation (CBA) based PVI.</p><p><strong>Methods and result: </strong>A total of 550 consecutively enrolled patients underwent PFA or CBA index PVI. Repeat ablations in patients with symptomatic atrial arrhythmia recurrences were analysed. A total of 22/191 (12%) patients after index PFA-PVI and 44/359 (12%) after CBA-PVI underwent repeat ablation. Reconduction of any pulmonary vein (PV) was detected by multipolar spiral mapping catheter at each PV with careful evaluation of PV potentials and by 3D-mapping in 16/22 patients (73%) after PFA-PVI and in 33/44 (75%) after CBA-PVI (P = 1.000). Of 82 initially isolated PVs after PFA-PVI, 31 (38%) were reconducting; of 169 isolated PVs after CBA-PVI, 63 (37%) were reconducting (P = 0.936). Clinical atrial tachycardia occurred similarly in patients after PFA (5/22; 23%) and CBA (7/44; 16%; P = 0.515). Roof lines were set more often after PFA- (8/22; 36%) compared with CBA-PVI (5/44; 11%; P = 0.023). Repeat procedure duration [PFA: 87 (76, 123) min; CBA: 93 (75, 128) min; P = 0.446] was similar and fluoroscopy time [PFA: 11 (9, 14) min; CBA: 11 (8, 14) min; P = 0.739] equal between groups at repeat ablation.</p><p><strong>Conclusion: </strong>During repeat ablation after previous PFA- or CBA-based PVI, electrical PV-reconduction rates and patterns were similar.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11363872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implantable cardioverter defibrillators in paediatric patients: yet another example of healthcare divergence? 儿科植入式心律转复除颤器:医疗保健分歧的又一例证?
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-30 DOI: 10.1093/europace/euae230
Elizabeth DeWitt, Jan Janousek, Susan P Etheridge
{"title":"Implantable cardioverter defibrillators in paediatric patients: yet another example of healthcare divergence?","authors":"Elizabeth DeWitt, Jan Janousek, Susan P Etheridge","doi":"10.1093/europace/euae230","DOIUrl":"10.1093/europace/euae230","url":null,"abstract":"","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11403278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increasing the reach: optimizing screening for atrial fibrillation-the STROKESTOP III study. 扩大覆盖范围:优化心房颤动筛查:STROKESTOP III 研究。
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-30 DOI: 10.1093/europace/euae234
Mashroor Khan, Michael Ingre, Fredrik Carlstedt, Anders Eriksson, Sofia Skröder, Johanna Star Tenn, Mårten Rosenqvist, Emma Svennberg

Aims: Atrial fibrillation (AF) is the most common type of cardiac arrythmia and is an important risk factor for ischaemic stroke. Many cases of AF remain undiagnosed due to its paroxysmal, intermittent, and often asymptomatic nature. Early detection of AF through screening and initiation of treatment with oral anticoagulants can prevent stroke, increase life expectancy, and decrease the cost of healthcare for the society. However, participation has been low in previous AF screening studies employing population screening. The aim of this study is to determine whether opportunistic screening is a superior method to increase participation in comparison to population screening. We hypothesize that opportunistic screening will significantly increase participation.

Methods and results: In our study, STROKESTOP III, a randomized prospective cohort study, we compare two different methods of AF screening in high-risk individuals: population screening vs. opportunistic screening. Sixteen different primary clinics in Värmland, Sweden, serving 75-76-year-old individuals (n = 2954), will be randomized to either population screening or opportunistic screening. The individuals will be instructed to record electrocardiogram (ECG) for 30 s, 3 times daily for 2 weeks, using a handheld one-lead ECG device. Patients with detected AF will be referred to their primary healthcare physician and offered treatment. The main objective of the study is to determine the rate of participation in opportunistic screening in comparison to population screening.

Conclusions: The STROKESTOP III study will provide valuable information on which screening method to use for improved participation in atrial fibrillation screening.

目的和假设:心房颤动(房颤)是最常见的心律失常类型,也是缺血性中风的重要危险因素。由于心房颤动具有阵发性、间歇性和无症状的特点,许多心房颤动病例仍未得到诊断。通过筛查及使用口服抗凝药(OACs)进行治疗来早期发现房颤可预防中风、延长预期寿命并降低社会医疗成本。然而,在以往采用人群筛查的房颤筛查研究中,参与率较低。本研究旨在确定与人群筛查相比,机会性筛查是否是提高参与率的更好方法。我们假设机会性筛查将显著提高参与率:在我们的研究 STROKESTOP III(一项随机前瞻性队列研究)中,我们比较了对高危人群进行房颤筛查的两种不同方法:人群筛查与机会性筛查。瑞典韦姆兰省 16 家不同的基层诊所将为 75-76 岁的患者(n = 2954)提供服务,这些患者将随机接受人群筛查或机会性筛查。将指导患者使用手持式单导联心电图仪记录心电图,每天 3 次,每次 30 秒,持续两周。检测出心房颤动的患者将被转诊至其初级保健医生并接受治疗。该研究的主要目的是确定机会性筛查与人群筛查的参与率。
{"title":"Increasing the reach: optimizing screening for atrial fibrillation-the STROKESTOP III study.","authors":"Mashroor Khan, Michael Ingre, Fredrik Carlstedt, Anders Eriksson, Sofia Skröder, Johanna Star Tenn, Mårten Rosenqvist, Emma Svennberg","doi":"10.1093/europace/euae234","DOIUrl":"10.1093/europace/euae234","url":null,"abstract":"<p><strong>Aims: </strong>Atrial fibrillation (AF) is the most common type of cardiac arrythmia and is an important risk factor for ischaemic stroke. Many cases of AF remain undiagnosed due to its paroxysmal, intermittent, and often asymptomatic nature. Early detection of AF through screening and initiation of treatment with oral anticoagulants can prevent stroke, increase life expectancy, and decrease the cost of healthcare for the society. However, participation has been low in previous AF screening studies employing population screening. The aim of this study is to determine whether opportunistic screening is a superior method to increase participation in comparison to population screening. We hypothesize that opportunistic screening will significantly increase participation.</p><p><strong>Methods and results: </strong>In our study, STROKESTOP III, a randomized prospective cohort study, we compare two different methods of AF screening in high-risk individuals: population screening vs. opportunistic screening. Sixteen different primary clinics in Värmland, Sweden, serving 75-76-year-old individuals (n = 2954), will be randomized to either population screening or opportunistic screening. The individuals will be instructed to record electrocardiogram (ECG) for 30 s, 3 times daily for 2 weeks, using a handheld one-lead ECG device. Patients with detected AF will be referred to their primary healthcare physician and offered treatment. The main objective of the study is to determine the rate of participation in opportunistic screening in comparison to population screening.</p><p><strong>Conclusions: </strong>The STROKESTOP III study will provide valuable information on which screening method to use for improved participation in atrial fibrillation screening.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11413581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical impact of atrial fibrillation progression in patients with heart failure with preserved ejection fraction: A report from the CHART-2 Study. 射血分数保留型心力衰竭患者心房颤动进展的临床影响:CHART-2 研究报告
IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-30 DOI: 10.1093/europace/euae218
Tomohiro Ito, Takashi Noda, Kotaro Nochioka, Takashi Shiroto, Nobuhiko Yamamoto, Hiroyuki Sato, Takahiko Chiba, Yuhi Hasebe, Makoto Nakano, Hiroyuki Takahama, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa, Satoshi Yasuda

Aims: Atrial fibrillation (AF) frequently coexists with heart failure with preserved ejection fraction (HFpEF), and clinical outcomes of patients with AF vary depending on its subtype. While AF progression characterized by the transition from paroxysmal AF to persistent AF is sometimes observed, the incidence and clinical impact of AF progression in patients with HFpEF remain to be explored.

Methods and results: We enrolled patients with HFpEF and paroxysmal AF from the Chronic Heart Failure Analysis and Registry in the Tohoku District-2 (CHART-2) Study. AF progression was defined as the transition from paroxysmal AF to persistent AF. A total of 718 patients (median age: 72 years, 36% were female) were enrolled. For a median follow-up of 6.0 years (interquartile range: 3.0-10.2 years), AF progression occurred in 105 patients (14.6%), with a cumulative incidence of 16.7% at 10 years. In the multivariable Cox proportional hazards model, previous hospitalization for heart failure [hazard ratio (HR) 1.74, 95% confidence interval (CI) 1.16-2.60; P = 0.007] and left atrial diameter (per 5-mm increase) (HR 1.37, 95% CI 1.20-1.55; P < 0.001) were significantly associated with AF progression. Furthermore, AF progression was significantly linked to worsening heart failure (adjusted HR 1.68, 95% CI 1.18-2.40; P = 0.004). Notably, 27 cases (26%) of worsening heart failure occurred within 1 year following AF progression.

Conclusion: In patients with HFpEF, AF progression is significantly associated with adverse outcomes, particularly worsening heart failure. An increased risk is observed in the early phases following progression to persistent AF.

Registration: Clinical Trials.gov Identifier: NCT00418041.

目的:心房颤动(AF)经常与射血分数保留型心力衰竭(HFpEF)并存,心房颤动患者的临床预后因其亚型而异。虽然有时会观察到房颤进展,其特征是从阵发性房颤过渡到持续性房颤,但房颤进展在射血分数保留型心力衰竭患者中的发生率和临床影响仍有待探讨:我们从 "东北地区慢性心力衰竭分析和登记-2(CHART-2)研究 "中招募了患有高频心力衰竭和阵发性房颤的患者。房颤进展的定义是从阵发性房颤转变为持续性房颤。共有 718 名患者(中位年龄:72 岁,36% 为女性)被纳入研究。在中位随访 6.0 年(四分位间范围:3.0-10.2 年)期间,105 名患者(14.6%)出现房颤进展,10 年的累积发生率为 16.7%。在多变量考克斯比例危险模型中,既往因心力衰竭住院(危险比 [HR] 1.74,95% 置信区间 [CI] 1.16-2.60;P=0.007)和左心房直径(每增加 5 毫米)(HR 1.37,95% CI 1.20-1.55;PConclusion:在高频心衰患者中,房颤进展与不良预后,尤其是心衰恶化密切相关。在进展为持续性房颤后的早期阶段观察到风险增加:注册:ClinicalTrials.gov Identifier:NCT00418041。
{"title":"Clinical impact of atrial fibrillation progression in patients with heart failure with preserved ejection fraction: A report from the CHART-2 Study.","authors":"Tomohiro Ito, Takashi Noda, Kotaro Nochioka, Takashi Shiroto, Nobuhiko Yamamoto, Hiroyuki Sato, Takahiko Chiba, Yuhi Hasebe, Makoto Nakano, Hiroyuki Takahama, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa, Satoshi Yasuda","doi":"10.1093/europace/euae218","DOIUrl":"10.1093/europace/euae218","url":null,"abstract":"<p><strong>Aims: </strong>Atrial fibrillation (AF) frequently coexists with heart failure with preserved ejection fraction (HFpEF), and clinical outcomes of patients with AF vary depending on its subtype. While AF progression characterized by the transition from paroxysmal AF to persistent AF is sometimes observed, the incidence and clinical impact of AF progression in patients with HFpEF remain to be explored.</p><p><strong>Methods and results: </strong>We enrolled patients with HFpEF and paroxysmal AF from the Chronic Heart Failure Analysis and Registry in the Tohoku District-2 (CHART-2) Study. AF progression was defined as the transition from paroxysmal AF to persistent AF. A total of 718 patients (median age: 72 years, 36% were female) were enrolled. For a median follow-up of 6.0 years (interquartile range: 3.0-10.2 years), AF progression occurred in 105 patients (14.6%), with a cumulative incidence of 16.7% at 10 years. In the multivariable Cox proportional hazards model, previous hospitalization for heart failure [hazard ratio (HR) 1.74, 95% confidence interval (CI) 1.16-2.60; P = 0.007] and left atrial diameter (per 5-mm increase) (HR 1.37, 95% CI 1.20-1.55; P < 0.001) were significantly associated with AF progression. Furthermore, AF progression was significantly linked to worsening heart failure (adjusted HR 1.68, 95% CI 1.18-2.40; P = 0.004). Notably, 27 cases (26%) of worsening heart failure occurred within 1 year following AF progression.</p><p><strong>Conclusion: </strong>In patients with HFpEF, AF progression is significantly associated with adverse outcomes, particularly worsening heart failure. An increased risk is observed in the early phases following progression to persistent AF.</p><p><strong>Registration: </strong>Clinical Trials.gov Identifier: NCT00418041.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368130/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141987683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Europace
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1